Endocrine therapy in the treatment of metastatic breast cancer

Seminars in Oncology

Volumn 28, Issue 3, 2001, Pages 291-304

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; CORTICOSTEROID; DROLOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; IDOXIFENE; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MIPROXIFENE PHOSPHATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOROZOLE;

ADRENALECTOMY; ALGORITHM; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HYPOPHYSECTOMY; NONHUMAN; OVARIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0034984594     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90122-8     Document Type: Article

References (89)

1. Cancer statistics, 2001
2. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
3. Hormonal therapy and chemotherapy
4. Control of invasion and angiogenesis
5. Angiogenesis and cancer metastases: Therapeutic approaches
6. Natural history of breast cancer
7. Treatment of metastatic breast cancer: Present and future prospects
8. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy: Comparison of consecutive series of patients in 1950s, 1960s, and 1970s
9. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
10. Endocrine therapy of metastatic breast cancer
11. Relationship between c-erbB- 2 protein product expression and response to endocrine therapy in advanced breast cancer
12. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
13. On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new method of treatment, with illustrative cases
14. The role of progestins and progesterone receptors in the treatment of breast cancer
15. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
16. Treatment of breast cancer
17. Use of tamoxifen for breast cancer: Twenty-eight years later
18. Tamoxifen for early breast cancer: An overview of the randomised trials
19. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
20. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
21. Tamoxifen, serum lipoproteins and cardiovascular risk
22. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
23. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
24. Update of the NCCN guidelines for treatment of breast cancer
25. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse
26. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB)
27. Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women
28. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
29. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
30. Phase I and II studies of toremifene
31. Phase III trials of toremifene vs tamoxifen
32. Effect of toremifene in breast cancer patients. Preliminary communication
33. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment
34. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
35. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment
36. Preclinical data for droloxifene
37. Endocrine therapies of breast cancer
38. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent
39. Metabolism of the 4-IODO derivative of tamoxifen by isolated rat hepatocytes
40. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
41. Idoxifene: Report of a phase I study in patients with metastatic breast cancer
42. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent rumors
43. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice
44. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice
45. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
46. Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women
47. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
48. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
49. Phase II evaluation of Ly 156758 in metastatic breast cancer
50. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer
51. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
52. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
53. A potent specific pure antiestrogen with clinical potential
54. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
55. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
56. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
57. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
58. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes
59. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
60. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen
61. Low-dose aminoglutethimide with or without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research
62. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study
63. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in post-menopausal patients with advanced breast cancer
64. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in post-menopausal women with advanced breast carcinoma
65. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
66. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women-Combined analysis from two identically designed multicenter trials
67. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer
68. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer
69. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of pos-menopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multi-institutional trials
70. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
71. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
72. Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: Relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group)
73. Vorozole (Rivizor): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure
74. Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study
75. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer
76. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
77. 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer
78. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer
79. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer
80. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
81. Multicenter, phase II trial of exemestane as third-line hormonal therapy of post-menopausal women with metastatic breast cancer
82. A phase II study of exemestane in metastatic breast cancer (MBC) patients failing nonsteroidal aromatase inhibitors
83. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
84. Exemestane is superior to megestrol acetate after tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
85. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
86. Ovarian ablation as treatment for young women with breast cancer
87. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer
88. Multiple endocrine therapy (Rx) in the management of advanced breast cancer
89. Update on endocrine therapy for breast cancer